Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The pharmaceutical distribution contract with OptumRx will expire in June.

Cardinal Health Won't Renew OptumRx Distribution Pact. Guidance Is Unchanged.

UnitedHealth Group

Cardinal Health said on Monday its pharma distribution contracts with UnitedHealth Group Inc's OptumRx unit will not be renewed after they expire at the end of June.

Cardinal Health says contracts with UnitedHealth's OptumRx will not be renewed

Cardinal Health Inc. ‘s stock CAH, +2.07% fell 3.6% early Monday, after the pharmaceuticals distributor and medical lab products maker said its contracts with pharmacy benefits manager OptumRx will expire at the end of June and will not be renewed. The Dublin, Ohio-based company said it still expects 2024 EPS of $7.20 to $7.35 despite the end of the contract, which generated 16% of its revenue in fiscal 2023.

Cardinal Health's stock slides 3.6% after announcing contract with OptumRx will not be renewed after end-June

DUBLIN, Ohio , April 22, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. The company reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance of $7.20 to $7.35.

Cardinal Health Reaffirms Fiscal 2024 non-GAAP EPS Guidance and Long-term Targets Amidst Nonrenewal of OptumRx Customer Contracts

Cardinal Health is overvalued, with a dividend yield lower than its historical average and a high P/E ratio. Growth projections for the Company are moderate, with a projected growth rate of 7.8% for the next 5 years. Return projections using the discounted dividend model suggest that CAH is still overvalued, with a fair price of around $79 compared to its current price of $106.

Cardinal Health: Solid Business But Overvalued

In the latest trading session, Cardinal Health (CAH) closed at $107.03, marking a +1.84% move from the previous day.

Cardinal Health (CAH) Increases Despite Market Slip: Here's What You Need to Know

Forestar Group

Blue Owl Capital Corp

CPI, the Consumer Price Index, is a metric used to gauge the rate of inflation and deflation. It's released by the Bureau of Labor Statistics (BLS) and reports the monthly fluctuations in consumer goods and services prices.

CPI Shock Waves: 3 Undervalued Stocks to Ride the Volatility

Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Cardinal Health, Inc. (CAH) is Attracting Investor Attention: Here is What You Should Know

Baxter

Fresenius Medical Care

Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.

3 Medical Device Stocks With Solid Dividend Yield: CAH & Others

Ares Capital

Strong buy companies are a great place to start when seeking companies to invest in. It can require a fair amount of effort and research to find stocks that are also trading at a bargain rate.

Wall Street Favorites: 3 Bargain Stocks With Strong Buy Ratings for April 2024

Cardinal Health (CAH) concluded the recent trading session at $109.47, signifying a -0.41% move from its prior day's close.

Here's Why Cardinal Health (CAH) Fell More Than Broader Market

Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Cardinal (CAH) is Poised to Beat Earnings Estimates Again

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Reasons to Add Cardinal Health (CAH) to Your Portfolio Now

The Consumer Health Logistics Center will be located in Central Ohio and serve as a centralized hub for distribution of consumer health products COLUMBUS, Ohio , April 2, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) announced that construction has begun for a new 350,000 square-foot logistics center in Columbus, Ohio, that will serve as a centralized replenishment center for the distribution of over-the-counter consumer health products in support of its core pharmaceutical business. Located in the Rickenbacker Global Logistics Park, the Consumer Health Logistics Center will be the fourth Cardinal Health distribution facility in Central Ohio, along with its corporate headquarters in Dublin, Ohio.

Cardinal Health announces location of pharmaceutical distribution center for over-the-counter products

Asbury Automotive Group

Cencora Inc

General Motors

We believe that stocks like General Motors (GM), Cardinal Health (CAH), Cencora (COR), Alta Equipment (ALTG) and Asbury (ABG) should be on an investor's watchlist.

5 Broker-Loved Stocks That Hold Promise Despite Volatility

Applied Materials

Installed Building Products

NetApp

Ralph Lauren

NetApp (NTAP), Installed Building (IBP), Ralph Lauren (RL), Applied Materials (AMAT), and Cardinal Health (CAH) could outperform the market this year.

5 Solid Dividend Growth Stocks to Buy

DUBLIN, Ohio , March 26, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2024 on May 2, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2024 on May 2

Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Growth Investors Will Love Cardinal (CAH)

Hercules Capital

The Cash Cow Cavalry: 3 Stocks Leading the Charge to Profitability

Atmos Energy

Balchem

Casey's General Stores

Colgate-Palmolive

Low-beta stocks like Atmos Energy Corporation (ATO), Balchem Corporation (BCPC), Cardinal Health, Inc. (CAH), Casey's General Stores, Inc. (CASY) and Colgate-Palmolive Company (CL) are a safe bet amid the ongoing market volatility.

5 Low-Beta Stocks for Safe Returns as Inflation Rises Again

DUBLIN, Ohio , March 15, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions reduction targets. Targets are considered science-based if they align with what the latest climate science says is necessary to limit global warming to 1.5°C above pre-industrial levels.

Cardinal Health announces approved science-based climate targets; expands focus across the supply chain

SkyWest

Undervalued stocks are typically always a solid investment option in a bullish or bearish market due to the fact that they offer considerable upside.  Solid fundamentals are the backbone of a company's overall success.

The 3 Most Undervalued Stocks With Solid Fundamentals to Buy in March 2024

Cardinal Health, Inc. (CAH) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Cardinal Health (CAH) Hits 52-Week High: What's Driving It?

Centene

Deutsche Bank

Group 1 Automotive

We believe that stocks like General Motors (GM), Cardinal Health (CAH), Deutsche Bank (DB), Group 1 (GPI) and Centene (CNC) should be on an investor's watchlist.

News for Cardinal Health Stock (CAH)